The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Boceprevir and HIV Drug Can Interact Dangerously

Back to News Homepage

Next

Concurrent Hepatitis C and Chronic Obstructive Pulmonary Disease

Triple Therapy with GS-7977 Successful Against Hepatitis C

May 7, 2012

Print this page

In just three weeks, the Hepatitis C drug in development, GS-7977, led to a sustained virologic response in over 90 percent of patients when paired with ribavirin and pegylated interferon.

GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks

Liz Highleyman

Produced in collaboration with hivandhepatitis.com

Published: 30 April 2012

Adding GS-7977 to pegylated interferon and ribavirin for 12 weeks led to a sustained response rate of 90% for previously untreated chronic hepatitis C patients with difficult-to-treat genotype 1, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.

Last year’s approval of the first direct-acting antiviral agents has changed the face of hepatitis C treatment. The first such drugs still must be taken with pegylated interferon and ribavirin, but they increase cure rates and offer the potential for shorter treatment.

Continue reading this entire article:
http://www.aidsmap.com/GS-7977-with-interferonribavirin-cures-most-treatment-naive-hepatitis-C-patients-in-12-weeks/page/2333885/

25 Comments
Share
Share

Previous

Boceprevir and HIV Drug Can Interact Dangerously

Back to News Homepage

Next

Concurrent Hepatitis C and Chronic Obstructive Pulmonary Disease

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.